Abstract. Affibody protein is an engineered protein scaffold with a three-helical bundle structure. Affibody molecules of small size ͑7 kD͒ have great potential for targeting overexpressed cancer biomarkers in vivo. To develop an Affibody-based molecular probe for in vivo optical imaging of epidermal growth factor receptor ͑EGFR͒ positive tumors, an anti-EGFR Affibody molecule, Ac-Cys-Z EGFR:1907 ͑7 kD͒, is site-specifically conjugated with a near-IR fluorescence dye, Cy5.5-mono-maleimide. Using fluorescent microscopy, the binding specificity of the probe Cy5.5-Z EGFR:1907 is checked by a high-EGFR-expressing A431 cell and low-EGFR-expressing MCF7 cells. The binding affinity of Cy5.5-Z EGFR:1907 ͑K D ͒ to EGFR is 43.6± 8.4 nM, as determined by flow cytometry. For an in vivo imaging study, the probe shows fast tumor targeting and good tumor contrast as early as 0.5 h postinjection ͑p.i.͒ for A431 tumors, while MCF7 tumors are barely visible. An ex vivo imaging study also demonstrates that Cy5.5-Z EGFR:1907 has high tumor, liver, and kidney uptakes at 24 h p.i.. In conclusion, Cy5.5-Z EGFR:1907 shows good affinity and high specificity to the EGFR. There is rapid achievement of good tumor-to-normal-tissue contrasts of Cy5.5-Z EGFR:1907 , thus demonstrating its potential for EGFR-targeted molecular imaging of cancers.
Introduction
Epidermal growth factor receptor ͑EGFR͒ is a transmembrane protein belonging to ErbB oncogene family. Overexpression of EGFR has been frequently detected in a wide range of human tumors, for example, non-small-cell lung cancer, small-cell carcinoma of the head and neck, esophageal cancer, gastric cancer, gliomas, colon cancer, pancreas cancer, breast cancer, ovarian cancer, bladder cancer, kidney cancer, and prostate cancer. 1 Recently, EGFR has emerged as an attractive target for cancer therapy. EGFR-targeted therapies including the use of monoclonal antibodies ͑MAbs: cetuximab, panitumumab͒ and tyrosine kinase inhibitors ͓TKIs: gefitinib ͑Iressa͒, erlotinib ͑Tarceva͒, lapatinib ͑Tykerb͔͒ have been developed and extensively studied. [2] [3] [4] Meanwhile, molecular probes for EGFR imaging have also been under active investigation. [5] [6] [7] It is expected that EGFR-specific molecular probes could potentially be used for early detection of EGFR positive tumors and metastases, prediction of efficacy for EGFR-targeted therapy, and for guidance in surgery etc.
A variety of small-molecule-based EGFR ligands and anti-EGFR antibodies are available for developing molecular probes for different imaging modalities. However, it has been found that small molecules labeled with radionuclides generally showed rapid blood clearance, but very low tumor uptake and poor tumor imaging quality. [5] [6] [7] Moreover, these small molecules are relatively sensitive to chemical modifications with large bulky tags, and they may not be a good platform for developing optical imaging probes for EGFR. On the other hand, fluorescent dyes or radiolabeled anti-EGFR MAbs have been prepared and have demonstrated good tumor uptake. However, because of slow tumor targeting ability and slow clearance [8] [9] [10] of the MAbs, the tumors can be visualized only at many hours or even days after injection of the probes. Substantial improvement of EGFR molecular probes is still required for preclinical and clinical applications.
Small protein scaffolds have shown great potential for recognizing a variety of biomarkers. 11, 12 Among them Affibody molecules are a promising generalizable platform for developing imaging or therapeutic agents for different molecular targets. [13] [14] [15] Affibody molecules are small, engineered proteins with only 58 amino acid residues and a three-helix bundle scaffold structure, while they display a binding surface as large as antibodies. High-affinity Affibody proteins ͑lower nanomolar or even picomolar͒ against different targets could be obtained through the phage display technique and affinity maturation. Because of the small size ͑7 kDa͒ and high affinities, Affibody proteins generally show fast tumor targeting ͑within a half hour͒, high tumor uptake, and quick clearance from normal tissues. Moreover, Affibody proteins can be chemically synthesized with reasonable yield using conventional solid-phase peptide synthesis. Synthetic Affibodies retain the high binding specificity and affinity. Anti-human epidermal growth factor receptor 2 ͑HER2͒ Affibody molecules have been labeled with various radionuclides, organic dyes, and nanoparticles for imaging applications from cell to small animal imaging and even human. [16] [17] [18] Dual-dye-labeled Affibody or even tri-labeled Affibody have also been reported. 19 Overall, an Affibody protein scaffold has been proven to be an excellent platform for molecular probe development.
An anti-EGFR Affibody protein, Z EGFR:1907 , has shown strong binding ͑K D = 5.4 nM͒ to EGFR with no cross-binding to other growth factor receptors. 20 It has been found that 64 In-labeled Z EGFR:1907 display fast and high tumor uptake ͑ϳ10% inject dose ͑ID͒/g and 3 to 6%ID/ g, respectively, at 4 h p.i.͒, as well as quick clearance from blood pool ͑ϳ5%ID/ g and 1.5 to 2%ID/ g, respectively, 4 h p.i.͒ and EGFR nonexpression tissues [20] [21] [22] [23] [24] ͑except kidney͒. We thus hypothesized that this Affibody could be a good protein for developing optical imaging probes for near-infrared ͑NIR͒ fluorescent imaging of EGFR positive tumors. In this research, a cysteine residue was first added to the N-terminus of Z EGFR:1907 . The resulting chemically synthesized protein, Ac-Cys-Z EGFR:1907 ͑Ac-CVDNKFNKEMWAAWEEIRNLP-NLNGWQMTAFIASLVDDPSQSANLLAEAKKLNDAQAP-K-NH 2 ͒, was site specifically conjugated with a NIR dye, Cy5.5-mono-maleimide. The optical probe Cy5.5-Z EGFR:1907 was further evaluated in the EGFR positive human epithelial carcinoma A431 cell culture and tumor-bearing mice.
Materials and Methods

General Material and Reagent
Cy5.5-mono-maleimide was purchased from GE Healthcare ͑Piscataway, New Jersey͒. Dichloromethane, triethylamine, N-hydroxybenzotriazole hydrate ͑HOBT͒, diisopropylcarbodiimide ͑DIC͒, ethyl acetate, and dithiothriotol ͑DTT͒ were purchased from Sigma-Aldrich Chemical Co. ͑St. Louis, Missouri͒. Dimethylsulfoxide ͑DMSO͒ and ethyl acetate were purchased from Fisher Scientific ͑Pittsburgh, Pennsylvania͒. All the other standard reagents were purchased from SigmaAldrich Chemical Co. All chemicals were used without further purification.
The Affibody analog, Ac-Cys-Z EGFR:1907 , was prepared by a solid phase peptide synthesis method as previously described. 21 Reverse-phase high-performance liquid chromatography ͑RP-HPLC͒ was performed on a Dionex Ultimate 3000 HPLC system ͑Dionex Corporation, Sunnyvale, California, for analysis and preparation of peptides and bioconjugates͒ equipped with a photodiode array detector. Five UV wavelengths ͑218, 254, 280, 500, and 675 nm͒ were monitored for all the experiments. Analytical RP-HPLC column from Sorbent Tech ͑Atlanta, Georgia͒ ͑Grace Vydac C4, 4.6 ϫ 250 mm͒ was used for analysis of the labeled small protein. 
Synthesis of Cy5.5-Z EGFR:1907
The general procedure for preparation of Cy5.5-Z EGFR:1907 is as follows. The Affibody molecule Ac-Cys-Z EGFR:1907 was dissolved in freshly degassed phosphate buffer ͑0.1 M, pH 7.4͒ at a concentration of approximately 1 mg/ mL. The NIR dye Cy5.5-mono-maleimide ͑300 g͒ in DMSO was then added ͑1.5 equivalents per equivalent of the Affibody͒. After vortexing for 2 h, the reaction mixture was purified by the HPLC equipped with a Grace Vydac 214TP54-C4 column. Characterization of Cy5.5-Z EGFR:1907 was confirmed using MALDI-TOF-MS. The purity of the bioconjugate was confirmed by the analytical HPLC.
Fluorescence emission of Cy5.5-Z EGFR:1907 was measured on the Fluomax-3 fluorophotometer ͑HORIBA Jobin Yvon, Edison, New Jersey͒, and the spectrum was scanned from 650 to 850 nm with an increment of 1 nm. The wavelength of excitation light is 635 nm. The absorption spectrum of Cy5.5-Z EGFR:1907 was recorded on an Agilent 8453 UV-visible ChemStation ͑Agilent Technologies, Wilmington, Delaware͒. The spectrum was scanned from 500 to 850 nm with an increment of 1 nm.
Fluorescence Microscopy Study
The A431 and MCF7 cells were cultured in high-glucose Dulbecco modified eagle medium ͑DMEM͒ and modified eagle medium ͑MEM͒ respectively supplemented with 10% fetal bovine serum ͑FBS͒ and 1% penicillin-streptomycin ͑Invitro-gen Life Technologies, Carlsbad, California͒. The cell line was maintained in a humidified atmosphere of 5% CO 2 at 37°C, with the medium changed every other day. A confluent monolayer was detached with trypsin and dissociated into a single cell suspension for further cell culture.
For fluorescence microscopy study, A431 or MCF7 cells ͑1 ϫ 10 4 ͒ were cultured on the 35-mm MatTek glass-bottom culture dishes ͑Ashland, Massachusetts͒. After 24 h, the cells were washed with phosphate-buffered saline ͑PBS͒ and then incubated at 37°C with Cy5.5-Z EGFR:1907 ͑100 nM͒ for 1 h in dark. The EGFR-binding specificity of Cy5.5-Z EGFR:1907 in cell culture was verified by incubating the A431 and MCF7 cells with or without large amounts of ͑blocking dose͒ nonfluorescent Ac-Cys-Z EGFR:1907 peptide ͑10 M͒. After the incubation period, cells were washed three times with ice-cold PBS. The fluorescence signal of the cells was recorded using an Axiovert 200M fluorescence microscope ͑Carl Zeiss Mi-croImaging, Inc., Thornwood, New Jersey͒ equipped with a Cy5.5 filter set ͑Exciter, HQ 650/ 20 nm; Emitter, HQ 695/ 35 nm͒. An AttoArc HBO 100-W microscopic illuminator was used as a light source for fluorescence excitation. Images were taken using a thermoelectrically cooled chargecoupled device ͑CCD͒ ͑Micromax, model RTE/CCD-576, Princeton Instruments Inc., Trenton, New Jersey͒ and analyzed using MetaMorph Software version 6.2r4 ͑Molecular Devices Corporation, Downingtown, Pennsylvania͒.
Binding Affinity Measurement with Flow Cytometry
The flow cytometric analysis was performed as described in the literature with minor modification. 23 Samples were illuminated with a sapphire laser at 488 nm and a red laser at 635 nm on a BD FACSCalibur. The fluorescence and the forward-scattered and side-scattered light from 10,000 cells was detected at a rate of approximately 150 events/ s. Flow cytometric data were analyzed with FACSDiva Software ͑BD Biosciences, San Jose, California͒. Prior to the flow cytometric analysis, A431 cells seeded in 75-cm 2 flasks approximately 3 days before the experiment were trypsinized ͓0.05% trypsin to 0.02% ethylenediaminetetraacetic acid ͑EDTA͒, 2.5 mL, ϳ10 min, 37°C; Lonza Verviers S.P.R.L.͔ followed by a centrifugation ͑1000 g, 3 min͒. The pellet was subsequently resuspended in the binding buffer ͓PBS containing 1% bovine serum albumin ͑BSA͒ and 0.1% sodium azide ͑NaAz͔͒. A431 cells ͑0.2 M each, expressing ϳ2 ϫ 10 6 receptors/cell͒ were then distributed in Falcon tubes ͑15 mL͒. After centrifugation, the cells were incubated with 5 mL of Cy5.5-Z EGFR:1907 at different concentrations ͑ranging from 0.1 to 100 nM͒ for 1 h at room temperature in the dark, with continuous rocking. The cells were then centrifuged ͑178 g, 4 min, 4°C͒, washed with the binding buffer twice, resuspended in 500 L of binding buffer, and subjected to flow cytometric analysis. All procedures after the incubation with the probe were performed on ice with ice-cold buffers. A triplicate of the flow cytometric data was analyzed with GraphPad Prism 5 ͑GraphPad Software, San Diego, California͒ and a nonlinear regression one-site-specific model was used to calculate the K D of the probe.
Optical Imaging of A431 Tumors in Mice
All animal studies were carried out according to a protocol approved by the Stanford University Administrative Panels on Laboratory Animal Care ͑APLAC͒. Female athymic nude mice ͑nu/nu͒ at 4 to 6 weeks of age were injected subcutaneously in the shoulder with 5 ϫ 10 6 A431 or MCF7 cells suspended in 100 L of PBS. For the MCF7 mice model, 4.7 mg of estrogen was planted in the back 2 days before inoculation. The tumor-bearing mice were subjected to in vivo optical imaging studies 2 to 3 weeks after implantation.
In vivo fluorescence imaging was performed with an IVIS 200 small animal imaging system ͑Xenogen, Alameda, California͒. A Cy5.5 filter set ͑excitation 615 to 655 nm; emission 695 to 770 nm͒ was used for acquiring Cy5.5-Z EGFR:1907 fluorescence in vivo. Identical illumination settings ͑lamp voltage, filters, f/stop, fields of view, binning͒ were used to acquire all images, and fluorescence emission was normalized to photons per second per centimeter squared per steradian ͑p / s / cm 2 / sr͒. Images were acquired and analyzed using Living Image 3.0 software ͑Xenogen, Alameda, California͒. For the positive control experiment, mice ͑n =3͒ were injected via tail vein with 0.5 nmol of Cy5.5-Z EGFR:1907 ͑20 nmol/ kg͒ and subjected to optical imaging at various time points p.i. For the blocking experiment, mice ͑n =3 for each probe also͒ were injected with the mixture of 300 g of Ac-Cys-Z EGFR:1907 and 0.5 nmol of Cy5.5-Z EGFR:1907 . IVIS-200 NIR fluorescent images were acquired using a 1-s exposure time ͑f / stop= 4, binning= 4͒.
To subtract the autofluorescence, optical imaging using an IVIS spectrum small animal imaging system was also performed on mice for ex vivo imaging. The mice injected with Cy5.5-Z EGFR:1907 were euthanized at 24 h p.i. and used for ex vivo fluorescence imaging. The tumor and other major tissues were dissected and placed on black papers. A slightly blue shifted excitation filters at 585 to 620 nm was used to measure the tissue autofluorescence. The background filter image was then subtracted from the primary filter image ͑excitation filter 620 to 655 nm͒ of Cy5.5-Z EGFR:1907 fluorescence by image-math. IVIS-spectrum NIR fluorescent images were acquired using a 5-s exposure time ͑f / stop= 4, binning= 4͒ because of the much narrower emission filter range ͑710 to 730 nm͒. The fluorescence images were acquired, and mean fluorescence flux ͑p / s / cm 2 / sr͒ for each sample was obtained.
Statistical Analysis
All the data are given as meansϮ SD ͑standard deviation͒ of n independent measurements. Statistical analysis was performed using a Student's t test. Statistical significance was assigned for P values Ͻ0.05. To determine tumor contrast, mean fluorescence intensities of the tumor area ͑T͒ at the shoulder of the animal and of the area ͑N͒ at the right flank ͑normal tissue͒ were calculated by the region-of-interest ͑ROI͒ function of Living Image software integrated with Igor ͑Wavemetrics, Lake Oswego, Oregon͒. Dividing T by N yielded the contrast between tumor tissue and normal tissue.
Results
Synthesis of Cy5.5-Z EGFR:1907
The Affibody small protein Ac-Cys-Z EGFR:1907 with a cysteine at the N terminal was successfully synthesized using a peptide synthesizer and purified by semipreparative HPLC. The peptide was generally obtained in 10% yield with over 95% purity ͓Fig. 1͑a͔͒. The purified Ac-Cys-Z EGFR:1907 was characterized by MALDI-TOF-MS. The measured molecular weight ͑MW͒ was consistent with the expected MW: m / z = 6690.0 for ͓M+H͔ + ͑Calculated MW= 6688.6͒. Ac-Cys-Z EGFR:1907 was then conjugated with Cy5.5-mono-maleimide in the PBS buffer and purified by HPLC. MS analysis verified the success preparation of the final product Cy5.5-Z EGFR:1907 ͑the observed MW: m / z = 7727.2 for ͓M+H͔ + , calculated MW ͓M+Na͔ + = 7727.4͒. The purity for the final product was over 95% ͑retention time: 25 min͒ ͓Fig. 1͑a͔͒, and the recovery yield of the probe was 47%. Spectrum study showed that Cy5.5-Z EGFR:1907 had similar absorption and fluorescence emission characteristics of free Cy5.5 dye, with ab = 680 nm and em = 696 nm ͓Fig. 1͑b͔͒.
Binding Specificity and Affinity of Cy5.5-Z EGFR:1907
To demonstrate the EGFR specificity and subcellular localization of Cy5.5-Z EGFR:1907 , the probe was incubated with A431 tumor cells and fluorescent microscopic imaging was performed. With an 1 h incubation at 37°C, intensive fluorescent signal was observed from the A431 cells membrane, and some of probe was also found to be inside of the cells ͑Fig. 2͒. Furthermore, the fluorescent signal from the cells could be significantly reduced by incubation of the cells with large excess of the Ac-Cys-Z EGFR:1907 ͑10 M͒, demonstrating the binding specificity of Cy5.5-Z EGFR:1907 ͑Fig. 2͒. The staining of low EGFR expression MCF7 is barely visible. The flow cytometry study was performed for measurement of the binding affinity of Cy5.5-Z EGFR:1907 . A representative flow cytometric analysis was shown in Fig. 3͑a͒ . The equilibrium dissociation constant K D was determined to be 43.6Ϯ 8.4 nM using a nonlinear regression one-site-specific model ͑Fig. 3͑b͒͒. The result for ex vivo tumor mice imaging at 24 h p.i., as shown in Fig. 5͑a͒ . Quantitative analysis showed that there is also large amount of probe trapped inside the kidney without clearance ͓Fig. 5͑b͔͒. The tumor-to-normal organ ͑except kidney͒ ratios are also high ͓Fig. 5͑c͔͒. For example, the ratios for tumor-to-lung and tumor-to-muscle are 5.6Ϯ 1.8 and 6.5Ϯ 0.4, respectively.
In Vivo and Ex Vivo Optical Imaging
Discussion
NIR fluorescent imaging, which uses neither ionizing radiation nor radioactive materials, is emerging as a promising modality that can complement traditional nuclear imaging methods. Optical molecular probes with high sensitivity, stability, fast targeting, and rapid clearance could be prepared. 17, 24, 25 Furthermore, optical imaging has very high resolution and shows great potential in clinical translation because of ͑1͒ the easy visualization of targeted tissues and ͑2͒ its use as supplementary visual aide to provide guidance in surgery. 26 Anti-EGFR Affibody, Z EGFR:1907 , was radiolabeled with 64 Cu in our recent study, which demonstrated good and fast tumor uptake and long retention. 21 It is also of a great interest to us to apply this Affibody molecule for developing an optical imaging probe, since there is a high demand for an EGFRtargeted optical probe with an ideal in vivo imaging profile.
To achieve this goal, Affibody analog Cys-Z EGFR:1907 was synthesized to render site-specific labeling using maleimide chemistry. Conjugation of the small protein with Cy5.5-mono-maleimide was successfully achieved, moreover the absorption and emission fluorescence properties of the probe remain very close to the unconjugated dye ͑Fig. 1͒. The probe Cy5.5-Z EGFR:1907 also showed good binding affinity to the A431 cell surface EGFR with a K D value of 43.6Ϯ 8.4 nM, which is considered sufficient for further in vivo evaluation, although target avidity was lower than that of the unmodified Affibody Z EGFR:1907 ͑ϳ5 nM͒ 20 ͓Fig. 3͑b͔͒. This result implies that the Affibody protein tolerates some N terminal modifications. Fluorescent microscopy of Cy5.5-Z EGFR:1907 showed that the majority of the probe bond to cell surface receptors after 1 h incubation, indicating the slow internalization of the Affibody molecule, which is also consistent with previous finding of the radioactive counterpart. 20, 21 More importantly, the specificity of the probe was verified with blocking by unlabeled Affibody ͑Fig. 2͒. These results warranted the further evaluation of the probe for in vivo EGFR-targeted tumor imaging.
Considering the high sensitivity of in vivo NIR imaging, 0.5 nmol of Cy5.5-Z EGFR:1907 was injected into A431 mice, and optical imaging studies were performed using IVIS-200 systems. Consistent with our expectation, good tumor uptakes and imaging qualities were observed ͓Fig. 4͑a͔͒. The A431 tumor was clearly delineated from normal tissues at as early as 0.5 h p.i. Quantification analysis of IVIS-200 images illustrated that tumor uptake reach plateau at 2 h ͓Fig. 4͑b͔͒. These results were attributable to the fast tumor targeting and rapid blood clearance abilities of Affibody molecules. Kidney uptake was also very high even at 24 h p.i., which is consisted with the radiometal labeled Affibody probes. 20, 21, 27 Further ex vivo imaging study exhibited that tumor-to-blood ratio reached 8.5Ϯ 3.6 at 24 h p.i. Autofluorescence was very obvious for the skin, which increases the background. Ex vivo imaging also revealed that tumor-to-muscle ratio was as high as 6.5Ϯ 0.4. These properties are favorable and demonstrate the use of the optical probe for intraoperative optical imaging.
In vivo optical imaging of EGFR has extensively been investigated using monoclonal antibody such as cetuximab ͑Er-bitux͒ labeled with NIR dyes. 8, 9, 28 Cy5.5-labeled cetuximab ͑abbreviated as Cy5.5-Erbitux͒ was reported to target EGFRhigh-expression MDA-MB-231 tumors and reached a maximum tumor to normal tissue ratio of ca 3 at 24 h p.i.. However, because of the slow localization and clearance of the antibody, Cy5.5-Erbitux showed almost no difference between MDA-MB-231 tumor with high EGFR expression and MCF-7 with low expression 9 before 6 h p.i. In contrast, Cy5.5-Z EGFR:1907 demonstrated fast tumor accumulation ͑T / N ratio= 2.64Ϯ 0.46 at 1 h p.i.͒ in the A431 model, while accumulation was very low in MCF7 tumor ͑T / N ratio = 1.62Ϯ 0.22 at 1 h p.i., P Ͻ 0.05͒, which is advantageous for both preclinical and clinical applications. NIR-dye-labeled EGF protein has also been reported for in vivo imaging. 29, 30 However, EGF as a natural ligand has some side effects such as stimulation of EGFR phosphorylation, causing vomiting and diarrhea. 30, 31 Finally, quantum dot conjugated with reduced EGF ͑r-Egf͒ was also reported, but the imaging result was poor and toxicity of quantum dot was a concern even at very low amount. 32 
Conclusion
Cy5.5-Z EGFR:1907 provided high-sensitivity, receptor-specific molecular imaging of EGFR-positive tumors. It showed good tumor-to-normal tissue ratios, fast tumor targeting ability, and quick blood clearance. Cy5.5-Z EGFR:1907 is a promising probe for further applications in EGFR-targeted optical imaging.
